(tert-butyloxy-carbonyl)-L-2-naphthylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (tert-butyloxy-carbonyl)-L-2-naphthylalanine
• 英文别名: Nα-tert-butyloxycarbonyl-2-naphthylalanine；N-tert-butoxycarbonyl-(2-naphthyl)alanine；(S)-N-BOC-2-Naphthylalanine；2-[(2-methylpropan-2-yl)oxycarbonyl-naphthalen-2-ylamino]propanoic acid
• 化学式: C₁₈H₂₁NO₄
• 分子量: 315.369
• InChiKey: DWNNJLXALCHZGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (tert-butyloxy-carbonyl)-L-2-naphthylalanine 、 ethyl 2-oximinooxamate 、 N,N'-二环己基碳二亚胺 以 吡啶 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 18.5h， 生成 (R)-5-(1-(N-Methyl-tert-butoxycarbonylamino)-2-(2-naphthyl)ethyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Compounds with growth hormone releasing properties

  摘要：

  本发明涉及化合物、含有这些化合物的组合物，以及它们用于治疗由生长激素缺乏引起的医学疾病的用途。

  公开号：

  US06350767B1

文献信息

• REVERSIBLE PROTEASE INHIBITORS
  申请人：ARRIS PHARMACEUTICAL CORPORATION

  公开号：EP0817778A1

  公开（公告）日：1998-01-14
• REVERSIBLE CYSTEINE PROTEASE INHIBITORS
  申请人：ARRIS PHARMACEUTICAL CORPORATION

  公开号：EP0832099A1

  公开（公告）日：1998-04-01
• Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds
  申请人：SHARMA D. Shubh

  公开号：US20060287330A1

  公开（公告）日：2006-12-21

  Melanocortin receptor-specific compounds of the general formula and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R 2a , R 2b , R 3a , R 3b , r, x and y are as defined in the specification, and the carbon atoms marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, including specifically treatment of obesity and related conditions.
• Peptides with Efficacy in Rescuing Melanocortin-4 Receptor Polymorphic Agonist Signaling
  申请人：Haskell-Luevano Carrie

  公开号：US20090176712A1

  公开（公告）日：2009-07-09

  Disclosed are novel ligands based on an AGRP template that can rescue endogenous melanocortin agonist and/or antagonist dysfunction at MCR polymorphisms. In particular, the present invention provides novel synthetic ligands based on AGRP templates that can rescue endogenous melanocortin agonist dysfunction at MC4R polymorphisms to treat children and adults with these mutations and increase their quality of life.
• US5776718A
  申请人：——

  公开号：US5776718A

  公开（公告）日：1998-07-07